AT500379B8 - Tau-proteine - Google Patents

Tau-proteine Download PDF

Info

Publication number
AT500379B8
AT500379B8 AT0017501A AT1752001A AT500379B8 AT 500379 B8 AT500379 B8 AT 500379B8 AT 0017501 A AT0017501 A AT 0017501A AT 1752001 A AT1752001 A AT 1752001A AT 500379 B8 AT500379 B8 AT 500379B8
Authority
AT
Austria
Prior art keywords
tau
tau proteins
normal
proteins
conformationally different
Prior art date
Application number
AT0017501A
Other languages
German (de)
English (en)
Other versions
AT500379A2 (de
AT500379B1 (de
AT500379A3 (de
Original Assignee
Axon Neuroscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0017501A priority Critical patent/AT500379B8/de
Application filed by Axon Neuroscience filed Critical Axon Neuroscience
Priority to EP02703586A priority patent/EP1355949B1/en
Priority to CNB028053133A priority patent/CN100503638C/zh
Priority to AT02703586T priority patent/ATE461941T1/de
Priority to JP2002563203A priority patent/JP4163955B2/ja
Priority to CNA2008101081547A priority patent/CN101307107A/zh
Priority to PCT/EP2002/000897 priority patent/WO2002062851A1/en
Priority to CA2437453A priority patent/CA2437453C/en
Priority to DK02703586.4T priority patent/DK1355949T3/da
Priority to DE60235746T priority patent/DE60235746D1/de
Priority to US10/470,928 priority patent/US7446180B2/en
Priority to RU2003126594/13A priority patent/RU2299889C2/ru
Priority to AU2002237296A priority patent/AU2002237296A1/en
Priority to ES02703586T priority patent/ES2339427T3/es
Publication of AT500379A2 publication Critical patent/AT500379A2/de
Priority to US12/264,694 priority patent/US20090123936A1/en
Publication of AT500379A3 publication Critical patent/AT500379A3/de
Publication of AT500379B1 publication Critical patent/AT500379B1/de
Application granted granted Critical
Publication of AT500379B8 publication Critical patent/AT500379B8/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0017501A 2001-02-02 2001-02-02 Tau-proteine AT500379B8 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine
US10/470,928 US7446180B2 (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
AT02703586T ATE461941T1 (de) 2001-02-02 2002-01-29 Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation
JP2002563203A JP4163955B2 (ja) 2001-02-02 2002-01-29 構造的に異常な形のタウタンパク質およびそれに対する特異抗体
CNA2008101081547A CN101307107A (zh) 2001-02-02 2002-01-29 tau蛋白
PCT/EP2002/000897 WO2002062851A1 (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
CA2437453A CA2437453C (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
DK02703586.4T DK1355949T3 (da) 2001-02-02 2002-01-29 Antistoffer mod konformationelt abnorme former af tau-protein der forekommer i væv ved Alzheimers sygdom
EP02703586A EP1355949B1 (en) 2001-02-02 2002-01-29 Antibodies against conformationally abnormal forms of tau protein present in Alzheimer's disease tissue
CNB028053133A CN100503638C (zh) 2001-02-02 2002-01-29 tau蛋白
RU2003126594/13A RU2299889C2 (ru) 2001-02-02 2002-01-29 Конформационно аномальные формы белков тау и специфические антитела к ним
AU2002237296A AU2002237296A1 (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto
ES02703586T ES2339427T3 (es) 2001-02-02 2002-01-29 Anticuerpos contra formas conformacionalmente anormales de proteina tau presente en tejidos con enfermedad de alzheimer.
DE60235746T DE60235746D1 (de) 2001-02-02 2002-01-29 Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation
US12/264,694 US20090123936A1 (en) 2001-02-02 2008-11-04 Conformationally abnormal forms of tau proteins and specific antibodies thereto

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine

Publications (4)

Publication Number Publication Date
AT500379A2 AT500379A2 (de) 2005-12-15
AT500379A3 AT500379A3 (de) 2009-02-15
AT500379B1 AT500379B1 (de) 2009-07-15
AT500379B8 true AT500379B8 (de) 2009-08-15

Family

ID=3658236

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine
AT02703586T ATE461941T1 (de) 2001-02-02 2002-01-29 Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02703586T ATE461941T1 (de) 2001-02-02 2002-01-29 Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation

Country Status (12)

Country Link
US (2) US7446180B2 (https=)
EP (1) EP1355949B1 (https=)
JP (1) JP4163955B2 (https=)
CN (2) CN100503638C (https=)
AT (2) AT500379B8 (https=)
AU (1) AU2002237296A1 (https=)
CA (1) CA2437453C (https=)
DE (1) DE60235746D1 (https=)
DK (1) DK1355949T3 (https=)
ES (1) ES2339427T3 (https=)
RU (1) RU2299889C2 (https=)
WO (1) WO2002062851A1 (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
CN100572392C (zh) * 2002-07-12 2009-12-23 阿克松神经科学研究和发展股份有限公司 截短tau蛋白
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
ES2321996B1 (es) * 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2009143556A1 (en) * 2008-05-30 2009-12-03 The University Of Sydney TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
EP2470211B1 (en) * 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
ITRM20100320A1 (it) 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
WO2012051498A2 (en) 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
EP2709728B1 (en) * 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
ES2656442T3 (es) * 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
RU2639537C2 (ru) 2011-10-07 2017-12-21 Ац Иммуне С.А. Фосфоспецифичные антитела, распознающие тау
HK1209768A1 (en) 2012-07-03 2016-04-08 Washington University Antibodies to tau
PE20150646A1 (es) * 2012-08-16 2015-05-21 Ipierian Inc Metodos de tratamiento de una tauopatia
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
PT2935326T (pt) 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
CN105143258B (zh) * 2013-03-15 2020-06-23 Ac免疫有限公司 抗Tau抗体和使用方法
HRP20200384T1 (hr) 2013-12-20 2020-06-12 F. Hoffmann - La Roche Ag Humanizirana anti-tau(ps422) protutijela i načini uporabe
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
EP4465050A3 (en) * 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
KR102770650B1 (ko) * 2015-07-06 2025-02-19 유씨비 바이오파마 에스알엘 타우 결합 항체
EP3334453A4 (en) 2015-08-13 2019-02-06 New York University ANTIBODY-BASED SPECIFIC MOLECULES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY, FOR TAU'S SPECIFIC ASP421 EPITOP
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
PL3484916T3 (pl) * 2016-07-12 2021-07-19 H. Lundbeck A/S Przeciwciała swoiste wobec hiperfosforylowanego białka tau i sposoby ich zastosowania
EP3496750A2 (en) 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
MA48595A (fr) 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
CN117820467A (zh) 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CN107686839B (zh) * 2017-09-25 2020-12-04 安徽朵能生物科技有限公司 微管结合蛋白cript、其治疗性突变体及其应用
CA3107788A1 (en) 2018-07-31 2020-02-06 Eli Lilly And Company Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
EP3768826B1 (en) 2019-03-18 2023-12-13 Regeneron Pharmaceuticals, Inc. Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
US20240101654A1 (en) 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733734A (en) * 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US20020164657A1 (en) * 2001-02-23 2002-11-07 Sharma Satish K. Assays for assessing A beta-Tau aggregation

Also Published As

Publication number Publication date
CN101307107A (zh) 2008-11-19
ES2339427T3 (es) 2010-05-20
DE60235746D1 (de) 2010-05-06
DK1355949T3 (da) 2010-05-25
RU2003126594A (ru) 2005-03-10
CN1492879A (zh) 2004-04-28
US20090123936A1 (en) 2009-05-14
JP2004532817A (ja) 2004-10-28
CA2437453C (en) 2013-06-11
AT500379A2 (de) 2005-12-15
ATE461941T1 (de) 2010-04-15
RU2299889C2 (ru) 2007-05-27
AT500379B1 (de) 2009-07-15
JP4163955B2 (ja) 2008-10-08
US7446180B2 (en) 2008-11-04
WO2002062851A1 (en) 2002-08-15
CN100503638C (zh) 2009-06-24
CA2437453A1 (en) 2002-08-15
AT500379A3 (de) 2009-02-15
US20040082763A1 (en) 2004-04-29
EP1355949A1 (en) 2003-10-29
AU2002237296A1 (en) 2002-08-19
EP1355949B1 (en) 2010-03-24
WO2002062851A8 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AT500379B1 (de) Tau-proteine
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
EP2147928A3 (en) Peptide-based immunization therapy for treatment of atherosclerososis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
DK1355919T3 (da) Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
EP2305286A3 (en) Treatment for Alzeimer's disease
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
DE602004011770D1 (de) Fusionsproteine
HUP0302589A2 (hu) A béta-amiloid peptidet felismerő humanizált ellenanyagok
WO2000078344A8 (en) Prion protein peptides and uses thereof
EP1541686A4 (en) ANTIBODY CONSTRUCTION USING AN MRL / LPR MOUSE
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
EA200400134A1 (ru) Терапевтический агент
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
DE602006019582D1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
WO2002046769A3 (en) A monoclonal antibody-based diagnostic assay for gamma fibrinogen
WO2006131562A3 (en) Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases

Legal Events

Date Code Title Description
PC Change of the owner

Owner name: AXON NEUROSCIENCE SE, CY

Effective date: 20191118

MK07 Expiry

Effective date: 20210202